HomeNewsBusinessAs COVID-19 fuels demand for online courses, here’s Ronnie Screwvala's next big gambit

As COVID-19 fuels demand for online courses, here’s Ronnie Screwvala's next big gambit

Among many things, the upGrad founder has set up a Rs 50 crore fund for acquisitions, but with a difference

April 15, 2020 / 20:23 IST
Story continues below Advertisement

Capitalising on a spurt in demand for online courses since the novel coronavirus, or COVID-19, outbreak, veteran entrepreneur Ronnie Screwvala has drawn up a multi-prong strategy.

Apart from shoring up resources to cater to the increasing demand for online professional courses, the co-founder of edtech start-up upGrad is also on the prowl for acquisitions, but with a slight difference.

Story continues below Advertisement

"I have set up a fund of Rs 50 crore for acquisitions," Screwvala told Moneycontrol. "A lot is happening in edtech, and there are some phenomenal entrepreneurs out there," he added.

But the businessman makes it clear, he is not there to 'save them,' and is not going to use the money to acquire companies. Instead, he is in talks with founders of promising start-ups who are in need of funds. Screwvala has offered them to merge their companies with upGrad, and then use the Rs 50 crore-corpus to fund their activities.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show